{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angio-oedema-anaphylaxis/background-information/causes-trigger-factors/","result":{"pageContext":{"chapter":{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors","depth":2,"htmlHeader":"<!-- begin field 28117250-a876-471c-81a7-a77c00b47328 --><h2>What are the causes/trigger factors?</h2><!-- end field 28117250-a876-471c-81a7-a77c00b47328 -->","summary":"","htmlStringContent":"<!-- begin item b977d8f9-45f5-40eb-9234-a77c00b46f57 --><!-- begin field 2ff60b17-60f2-4a35-b786-a77c00b47328 --><ul><li><strong>The causes/trigger factors of angio-oedema</strong> <strong>depend on the type of angio-oedema the person has </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">DermNet NZ, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>]<strong>.</strong><ul><li><strong>Acute allergic angio-oedema</strong> is usually mast cell-mediated (typically immunoglobulin E [IgE]-mediated) and histamine-induced. It almost always occurs with urticaria within 1–2 hours of exposure to the allergen, which includes certain foods (especially nuts, shellfish, milk, and eggs), certain drugs (including non-steroidal anti-inflammatory drugs [NSAIDs], penicillin, and vaccines), insect bites, latex, and contrast media for radiological investigations. </li><li><strong>Non-allergic angio-oedema</strong> is usually caused by increased bradykinin levels and includes non-allergic drug reactions, hereditary angio-oedema (HAE), and acquired angio-oedema (AAE).<ul><li><strong>Non-allergic drug reaction</strong> occurs days to months after taking the eliciting drug, most commonly angiotensin-converting enzyme (ACE) inhibitors. </li><li><strong>HAE</strong> is a rare and potentially life-threatening genetic abnormality. It is usually inherited in an autosomal-dominant manner, but about 25% of cases are thought to be due to new mutations (with no previous family history) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. In type 1 HAE (the most common form), there is a deficiency of the plasma protein C1 inhibitor (C1-INH), leading to the overproduction of bradykinin and a subsequent abrupt increase in vascular permeability. Type 2 HAE is characterized by the presence of normal or elevated levels of dysfunctional C1-INH, and type 3 (a very rare form) affects coagulation factor XII [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>]. Most attacks occur spontaneously, but mild trauma (for example dental work), viral illness, cold exposure, stress, pregnancy, or ingestion of certain foods and drugs are possible triggers (or aggravating factors).</li><li><strong>AAE, </strong>characterized by acquired deficiency of C1-INH, is even rarer than HAE<strong> </strong>and is usually secondary to lymphoma or a connective tissue disorder, such as systemic lupus erythematosus (SLE [which destroys the function of C1-INH]). Unlike HAE (which usually presents after puberty) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan and Greaves, 2005</a>], AAE usually presents after the fourth decade of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>]. The precipitating and aggravating factors of AAE are similar to those of HAE. </li></ul></li><li><strong>Idiopathic angio-oedema</strong> is usually a chronic and relapsing angio-oedema with an unknown cause. Many cases are thought to be autoimmune in nature, and about 30–50% of cases are associated with other autoimmune conditions (including SLE). </li></ul></li><li><strong>Anaphylaxis can be triggered by any of a very broad range of triggers, </strong>most commonly foods, drugs, and venom (including wasp and bee stings) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Panesar, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Wood, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ewan, 2016</a>], but in many cases no cause can be identified. A significant number of cases are idiopathic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>].<ul><li>Food is a common factor in children; drugs are much more common triggers in adults. </li><li>Any food or class of drug can cause anaphylaxis. However, nuts are the most common food cause, and anaesthetics, antibiotics (especially penicillin and cephalosporins), NSAIDs, and aspirin are the most commonly implicated drugs.</li><li>Rarely, anaphylaxis may be triggered by exercise [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ansley, 2015</a>]. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Muraro, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]</p><!-- end field 2ff60b17-60f2-4a35-b786-a77c00b47328 --><!-- end item b977d8f9-45f5-40eb-9234-a77c00b46f57 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","lastRevised":"Last revised in November 2018","chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}